Biological Activity
Pramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3].
In Vitro
Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3]. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture[4].
In Vivo
Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals[5]. Pramipexole dihydrochloride hydrate improves neurological recovery[5]. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke[5]. Animal Model: Male Wistar rats weighing 250-300 g (16-18 weeks old)[5] Dosage: 0.25 mg/kg, 1 mg/kg Administration: Intraperitoneal injection, at 1 hour, 6 hours, 12 hours, 18 hours post-occlusion Result: Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
